At under $40, is the Pfizer share price too cheap?

The Pfizer share price has risen 18% since it released its coronavirus vaccine. After its recent positive trading update, is the stock still too cheap?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Syringe and vial on blue background

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Since it announced that it had developed a Covid vaccine, the Pfizer (NYSE: PFE) share price has risen 18%. And it’s up almost 24% in the past year. Nonetheless, with a recent trading update that was excellent, in the views of many, Pfizer shares are now too cheap. But are they really? Yes, the company has managed to grow both profits and revenues. But these positives need to be balanced against some of the risks, especially as the company is facing multiple patent expirations in the middle of the current decade.

Recent trading update

In the first-quarter trading update, the positive impact of the vaccine could be seen. In fact, Q1 revenues were $14.6bn, 45% higher than the previous year. Profits were 48% higher at over $5bn.

These are clearly very strong results and demonstrate why Pfizer shares have managed to rise recently. The company also announced a quarterly dividend of 39 cents per share. This equates to an annual yield of roughly 4%. In comparison to the majority of pharma companies, this is high and I feel it offers a compelling reason for me to invest.

The recently strong financial results have equally demonstrated the positive impact of the coronavirus vaccine on the company. Indeed, Pfizer expects to generate $26bn in revenues from the vaccine alone. These revenues seem fairly safe. This is because it has signed a number of long-term contracts with governments around the world, many of which extend until 2024. The problem here is whether Pfizer can maintain its revenue growth after the need for coronavirus vaccinations has diminished.

What does the future hold?

Fortunately, Pfizer is not entirely reliant on the vaccine, and its core business has continued to perform strongly. Indeed, excluding the effect of the vaccine sales, revenue growth was still 8%.

Furthermore, the company has invested large amounts of cash into research and development, which will hopefully come to fruition in the future. In fact, as of March, Pfizer’s pipeline included 99 potential new therapies. Although not all of these will work out, it is still very promising. A new, successful drug would likely have a positive effect on the Pfizer share price.

Even so, there are risks that need to be pointed out. For example, many of Pfizer’s most successful drugs are coming up to patent expiration. These include the immunology drug Xeljanz in 2025 and Prevnar 13 in 2026. This means that generic competition will be able to enter the market. As such, it is vital that the company can continue to expand its pipeline in case sales of these drugs are negatively affected.

Is the Pfizer share price a bargain not to be missed?

This year the firm expects earnings per share of around $3.60. This gives Pfizer shares a price-to-earnings ratio of around 11, which does indicate a cheap valuation. After the success of the vaccine, it is also hoped that the company can build on this and remain a leader in innovation. Hopefully, this would be met with even larger profits in the future. So, I do believe the Pfizer share price is too cheap and has some upside potential. As such, I’m very tempted to add Pfizer shares to my portfolio. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Stuart Blair has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »